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Abstract
Background: The pathophysiological pathways resulting in Late Stent Thrombosis (LST) remain uncertain. Findings 
from animal studies indicate a role of the intrinsic coagulation pathway in arterial thrombus formation, while clinical 
studies support an association with ischemic cardiovascular disease. It is currently unknown whether differences in the 
state of the contact system might contribute to the risk of LST or Very Late Stent Thrombosis (VLST). We assessed the 
relation between levels of several components involved in the contact system and a history of LST and VLST, termed 
(V)LST in a cohort of 20 patients as compared to a matched control group treated with PCI.
Methods and Results: Activated factor XII (FXIIa), FXII zymogen (FXII), FXIIa-C1-esterase inhibitor (C1-inhibitor), 
Kallikrein-C1-inhibitor, FXIa-C1-inhibitor and FXIa-α1-antitrypsin (AT-inhibitor) complexes were measured by Enzyme-
linked immunosorbent assy (ELISA) methodology.
Cases and controls showed similar distributions in sex, age, baseline medications and stent type. Patients with a
history of (V)LST had a significantly greater stent burden and a higher number of previous myocardial infarctions
than the control patients.
There were no significant between-group differences in the plasma levels of the components of the contact system.
Conclusion: In a cohort of patients with a history of (V)LST, we did not observe differences in the activation state of the 
intrinsic coagulation system as compared to patients with a history of percutaneous coronary intervention without 
stent thrombosis.
Introduction
Coronary stents are routinely employed in percutaneous
coronary revascularization procedures and have signifi-
cantly decreased the rates of acute vessel closure and
restenosis[1]. The rate of stent thrombosis (ST) after per-
cutaneous coronary intervention (PCI) is estimated to be
as low as <1% of the cases following implantation of bare-
metal stents (BMS), of which approximately 50% occur
within the first month following implantation [2,3]. How-
ever, the potential fatality due to acute vessel closure, still
makes ST one of the most frightening complications after
percutaneous coronary intervention (PCI) [4,5]. During
the last years, concerns have been raised regarding later
occurrence of ST in drug-eluting stents (DES), in particu-
lar beyond the traditional 1-month timeframe[6-8]. The
actual incremental risk associated with DES has been an
issue of controversy.
Among others, discontinuation of antiplatelet therapy,
increased intrinsic platelet activity, incomplete stent
apposition, bifurcation stenting, renal insufficiency and
diabetes have been discussed as possible risk factors for
the development of late stent thrombosis (LST) (1-12
months) and very late stent thrombosis (VLST) (>12
months), and local inflammatory processes have been
shown to be associated with (V)LST in autopsy materials
[9-12]. However, the occurrence of (V)LST most likely
has a multifactorial origin and the exact pathophysiologi-
cal scenario leading to (V)LST remains uncertain.* Correspondence: povo@sus.no1 Institute of Medicine, University of Bergen, Bergen, Norway
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patients at high risk of (V)LST.
Contact activation, believed to be potentiated by nega-
tively charged surfaces, results in the activation of the
zymogen FXII to FXIIa and affects several pathophysio-
logical processes including hypotension, inflammation,
thrombosis and fibrinolysis[13-20].
Several components of the contact system have been
found to be related to coronary heart disease (CHD) [21-
27] and recent findings from animal studies indicate that
FXII might even be essential for arterial thrombus forma-
tion[28].
However, in contrast, other clinical studies have dem-
onstrated low FXII levels as a risk factor for coronary
heart disease or showed a U-shaped association to
risk[29-31]. Clinical settings and patient populations dif-
fer substantially between the existing clinical studies, and
even if an association of the contact system to CHD and
thrombosis seems likely, the exact mechanisms remain
poorly understood. Whether the activation state of the
contact system might be associated with the occurrence
of (V)LST has never been addressed.
The objective of the present study was to test the
hypothesis that patients having survived an event of
(V)LST have a generally different activation state of the
contact system as compared to matched patients without
a history of this condition.
Methods
Study design and patient population
The study was a single-centre cohort study (Risk markers
for Late in Stent Thrombosis (RIST)), in which 20
patients with a history of definitive (V)LST (as proposed
by the Academic Research Consortium [32]) were com-
pared to 32 PCI controls without (V)LST. These individu-
als were matched with respect to age, sex, current
antiplatelet medication and stent type [Seventy-five per-
cent of the (V)LST patients and 84.4% of the controls
treated with DES (TAXUS EXPRESS). The remaining
patients received BMS (Flexmaster or Express stents)].
Patients were included at the Stavanger University Hospi-
tal, Norway in March 2008.
All patients who could be identified from a local PCI
registry with a history of a definite (V)LST admitted dur-
ing the last 4 years were included in the study. Exclusion
criteria were age below 18 years or unwillingness or
inability to provide informed consent.
Assessment of previous clinical history, current and
previous medication and risk factors were based on hos-
pital records, angiographic records and personal inter-
view. Additionally, hospital journals were searched for
confirmation of reported data. Diabetes mellitus was
defined as either whole blood fasting glucose concentra-
tions above 6.1 mmol/L, two hour post glucose load con-
centrations above 10.0 mmol/L or medically treated
diabetes mellitus, and hypercholesterolemia was defined
as total cholesterol concentrations above 6.5 mmol/L or
medically treated hypercholesterolemia. Arterial hyper-
tension was defined as repeated blood pressure measure-
ments above 140/90 mmHg or treated hypertension.
Written informed consent was obtained from all
patients. The study was approved by the Regional Board
of Research Ethics and the Norwegian Health authorities
and conducted in accordance with the Helsinki declara-
tion of 1971, as revised in 1983.
Blood Sampling Procedures and Laboratory Measurements
Blood samples were drawn by puncture of an antecubital
vein with minimal stasis and centrifuged twice for 15
minutes at 2.000 × g and for 10 minutes at 11.000 × g at
18°C. Laboratory measurements were either performed
immediately following centrifugation or following storage
of the samples at -80°C.
A measure of FXIIa in citrated plasma was obtained by
enzyme linked immunosorbent assay (ELISA methodol-
ogy), using a specific monoclonal capture antibody (Mab
2/215) with no detectable recognition of FXII or FXIIa-
C1 inhibitor complexes [33]. The alkaline phosphatase
conjugated secondary antibody was a sheep polyclonal
antibody against FXIIa. Kits were supplied by Axis-
Shield, Dundee, United Kingdom.
FXII was measured in citrated plasma using ELISA,
based on a sheep polyclonal anti-FXII capture antibody
and a horseradish peroxidase conjugated goat polyclonal
anti-FXII secondary antibody (Enzyme Research Labora-
tories).
Complexes of FXIa, FXIIa, Kallikrein and C1-inhibitor
and complexes of FXIa and AT-inhibitor were measured
in EDTA plasma, to which soybean trypsin and benzami-
din (Sigma-Aldrich) was added to prevent contact activa-
tion during collection and processing, with enzyme-
linked immunosorbent assays (ELISAs), as previously
described with minor modifications[27]. The detection
limits were 0.095% for all four assays, respectively.
Hs-CRP was quantified in serum by a Tina quant® C-
reactive protein (latex) high sensitivity assay (Roche Diag-
nostics) [34].
Statistical methods
Approximately normally distributed variables were given
as mean and standard deviation, whilst skewed distribu-
tions were given as median and interquartile range. For
measurements of inhibitor complexes, values below the
cut-off limit of 0.095% were set to 0.095. The two sample
t-test was used to examine differences between the
patient and control group for normally distributed vari-
ables, whilst the Mann-Whitney-U test was applied to
test for the equality of the median of two samples of vari-
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association was applied for baseline categorical variables.
The statistical analyses were performed using SPSS ver-
sion 15.0. In all tests a two-tailed P-value of < 0.05 was
considered to statistically significant.
Results
21 patients with a history of (V)LST were identified from
our PCI registry. One patient was not included in the
study due to unwillingness to participate. The total study
population consisted of 52 patients. Twenty patients suf-
fered from a definite late or very late stent thrombosis
within the last 43 (median 10) months and there were 32
PCI controls without (V)LST (median follow-up time 15
months). Clopidogrel had been discontinued in all
patients prior to the development of (V)LST and after the
recommended treatment time of 6 - 12 months, with a
median discontinuation period of 202 days, whereas all
were receiving acetylsalicylic acid (ASA). Ninety percent
of the (V)LST patients were back on dual antiplatelet
therapy consisting of ASA and clopidogrel when they
were tested, and 91% of controls had been on continuous
dual antiplatelet treatment. The remaining 10 and 9%,
were only treated with ASA at the time of testing.
Baseline variables and demographics for the two groups
are displayed in Table 1 and baseline biochemical vari-
ables are displayed in Table 2. There was no significant
difference in the incidence of multivessel disease (50% vs
40.6%; p = 0.57) or minimum stent diameter 2.8 ± 0.4 mm
vs 2.9 ± 0.4 mm (Mean ± SD; p = 0.28) between the
(V)LST and the PCI control group. The total stent bur-
den was significantly greater in the (V)LST group as com-
pared to the PCI control group (total stent length 36.0
(30.5-48.0 mm) vs 20.0 (16.5-28.0 mm) (Median (25-75%
percentiles; p < 0.01). Specific variables related to (V)LST
are displayed in Table 3.
However, for none of the investigated components of
the contact system, significant differences could be
observed between the groups (Table 2).
Discussion
In the present study we could not demonstrate differ-
ences in the activation state of the contact system after
measuring several different components of the intrinsic
coagulation and the plasma kallikrein-kinin system
(PKKS) in patients with a history of (V)LST as compared
to controls.
Stent thrombosis is currently considered a multifacto-
rial problem related to patient, lesion, procedure, factors
related to blood coagulation and response to antiplatelet
therapy[3]. For understandable reasons much attention
has been on the contribution of platelets and the (lack of )
efficacy of platelet inhibiting agents. Stent thrombosis, in
particular following the implantation of DES, has been
mainly attributed to discontinuation or premature cessa-
tion of clopidogrel[5,35]. However, dual antiplatelet ther-
apy has not been found to entirely prevent the occurrence
of LST[36]. In addition, the occurrence of ST does not
seem to be strictly related to the time point of clopidogrel
cessation, as the event often occurs a long time after its
cessation. Moreover, the majority of patients do not
develop ST despite premature cessation of antiplatelet
medication. Consequently, it seems obvious that other
factors besides discontinuation of antiplatelet therapy
may be involved in the pathogenesis of ST.
Renne et al. provided a challenging new concept for
FXII in arterial thrombosis, showing impaired thrombus
stability in FXII deficient mice[28]. In addition they
showed that FXII deficient mice were partly protected
against ischemic stroke. Moreover, numerous clinical
studies have reported a role of different components of
the contact system and the PKKS in CHD, but detailed
pathophysiological mechanisms still remain poorly
understood. Increased FXII zymogen levels have primar-
ily been associated with a decrease in risk for MI and out-
come [29,31]. In contrast, elevated plasma FXIIa has been
shown to be associated with an increased risk of CHD,
the extent of coronary atheroma and with survival status
following an MI compared to healthy controls[21-24].
Moreover, FXIIa measured after an MI independently
predicted recurrent coronary occlusive events, [25] and
FXIIa in chest pain patients at hospital admission pre-
dicted long-term mortality [26] whereas other studies
failed to show clear associations of FXIIa to CHD[30].
Measurement of inhibited FXIIa (as the FXIIa-C1-inhibi-
tor complex) suggested that the level of this inhibitor
complex was associated with cardiovascular risk [27].
To our knowledge, late- and very late stent thrombosis
have not been described in relation to the contact and/or
plasma kallikrein-kinin system yet. In our analyses, we
examined different components of these systems and
their possible association to (V)LST. Low levels of inhibi-
tor complexes for the PKKS in both groups reflect a high
general risk for CHD [27]. However, for none of the mea-
sured biochemical variables, significant differences
between patients with a history of (V)LST and controls
were noted. Consequently, our results do not suggest a
role of the contact system in the pathogenesis of (V)LST.
The design of our study carries along several issues that
have to be considered with caution. Our ST population
consisted of patients suffering from both late- and very
late stent thrombosis, as well as of patients with implan-
tation of both DES and BMS. The pathophysiology of ST
may differ between these settings and may also lead to a
different involvement of the contact system.
The main limitation of the study is its retrospective
design, with no knowledge of the state of the contact sys-
tem at the time of the event. Ideally, also the discontinua-
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Page 4 of 7Table 1: Baseline clinical characteristics for patients with a history of late or very late stent thrombosis (LST/VLST) and 
controls.
Characteristics (V)LST group (n = 20) PCI Control group (n = 32) P
Demographics
Age (years)* 53.8 ± 8.6 56.9 ± 9.7 0.25
Female gender, n (%) 4 (20) 8 (25) 0.75
BMI kg/m2 * 26.0 ± 3.6 25.9 ± 3.7 0.87
Alcohol consumption (U/
week)*
3.8 ± 3.7 3.1 ± 3.4 0.50
Current smoking n (%) 7 (35) 9 (28) 0.76
Previous smoker n (%) 11 (55) 19 (59) 0.78
Angina pectoris (%) 3 (15) 7 (22) 0.72
Congestive heart failure n (%) 2 (10) 2 (6) 0.63
Hypertension n (%) 5 (25) 12 (38) 0.38
Diabetes mellitus n (%) 3 (15) 5 (16) 1.00
Hypercholesterolemia n (%) 9 (45) 11 (34) 0.56
Coagulation disorders n (%) 1 (5) 0 (0) 0.39
Current active infections n (%) 2 (10) 4 (13) 1.00
Chronic inflammatory 
disorders n (%)
1 (5) 5 (16) 0.39
Antiphospholipid syndrome n 
(%)
0 0 1.00
Pregnancy n (%) 0 0 1.00
Active malign disease n (%) 0 0 1.00
Previous MI n (%) 20 (100) 31 (97) 1.00
No of previous MI (n)* 1.8 ± 0.6 1.1 ± 0.4 <0.01
Family history of CHD n (%) 15 (75) 21 (66) 0.55
Previous VTE n (%) 0 0 1.00
Family history of VTE n (%) 5 (25) 5 (16) 0.48
Previous stroke n (%) 1 (5) 0 (0) 0.39
Previous PAD n (%) 1 (5) 1 (3) 1.00
Coronary artery bypass graft n 
(%)
1 (5) 2 (6) 0.85
Current medication
Acetylsalicylic acid n (%) 20 (100) 32(100) 1.00
Clopidogrel, n (%) 18 (90) 29 (91) 1.00
Warfarin n (%) 0 0 1.00
Angiotensin converting 
enzyme
inhibitor n (%)
11(55) 15(47) 0.78
Angiotensin-2 receptor 
blocker, n (%)
5 (25) 10 (31) 0.76
Beta blocker n (%) 9 (45) 12 (38) 0.77
Calcium channel blocker n (%) 0 (0) 2 (6) 0.52
Aldosteron antagonist n (%) 5 (25) 3 (9) 0.24
Insulin n (%) 1 (5) 0 (0) 0.39
Oral antidiabetics n (%) 1 (5) 4 (13) 0.64
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matched between the case and control group. However,
as most patients with a history of LST receive double
antiplatelet medication for an indefinite time period in
contrast to cessation of clopidogrel nine months to two
years following uncomplicated stent implantation, an
optimal matching regarding this parameter could not be
achieved.
In addition, the results of the present study are limited
by the restricted sample size. To achieve a statistical
power of 80% at a significance level of 5%, large differ-
ences in variables between the groups would have been
necessary, for example 7% for FXII, 31% for FXIIa, and
53% for FXIIa-Kallikrein-inhibitor. Whether potentially
smaller changes may be of biological importance is not
known and cannot be excluded by our data.
Conclusion
The present study does not suggest an association of the
activation state of the intrinsic coagulation system in rela-
tion to the occurrence of (V)LST.
NSAID n (%) 0 (0) 1 (3) 1.00
Statin n (%) 19 (95) 31 (97) 1.00
Hormone replacement 
therapy n (%)
0 (0) 1 (3) 1.00
*Mean ± SD; definer her diabetes, hyperkolesterolemi, family history of MI etc fra RACS)
Table 1: Baseline clinical characteristics for patients with a history of late or very late stent thrombosis (LST/VLST) and 
controls. (Continued)
Table 2: Baseline biochemical characteristics for patients with a history of late or very late stent thrombosis (LST/VLST) 
and controls.
Characteristics (V)LST group (n = 20) PCI Control group (n = 32) P
FXIIa (pM)* 70.0 (52.0-91.0) 67.5 (54.0-86.3) 0.95
FXII (%)* 99.0 (95.3-103.8) 99.0 (93.5-102.8) 0.79
FXIa-C1-inhibitor complex 
(%)*
0.17 (0.11-0.26) 0.21 (0.13-0.43) 0.25
FXIa-AT -complex (%)* 0.19 (0.15-0.27) 0.20 (0.15-0.28) 0.49
FXIIa-C1-inhibitor complex 
(%)*
0.11 (0.10-0.25) 0.13 (0.10-0.24) 0.80
Kallikrein-C1-inhibitor 
complex (%)*
0.10 (0.10-0.12) 0.10 (0.10-0.11) 0.93
Hs-CRP mg/L * 1.3 (1.0-3.1) 2.15 (1.0-3.8) 0.41
Se-creatinine (μmol/L)† 83.1 ± 18.0 85.9 ± 21.2 0.62
eGFR (ml/min)† 83 ± 19 79 ± 19 0.40
Hemoglobin g/dl† 14.0 ± 1.5 14.0 ± 1.4 0.94
Hematocrit %† 42.2 ± 4.1 41.8 ± 3.8 0.75
Thrombocytes (109/L)† 251 ± 42 257 ± 79 0.78
Leucocytes (109/L)† 6.6 ± 1.5 7.2 ± 2.4 0.25
Neutrophil count (109/L)† 3.8 ± 1.0 4.4 ± 1.8 0.21
Basophil count (109/L)† 0.01 ± 0.04 0.01 ± 0.03 0.95
Eosinophil count (109/L)† 0.23 ± 0.21 0.21 ± 0.12 0.61
Total Cholesterol (mmol/L)† 3.80 ± 0.61 3.96 ± 0.92 0.66
LDL-Cholesterol (mmol/L)† 1.8 ± 0.6 1.8 ± 0.6 0.91
HDL-Cholesterol (mmol/L)† 1.33 ± 0.28 1.36 ± 0.75 0.91
Triglycerides (mmol/L)† 1.4 ± 0.8 1.7 ± 0.8 0.27
HbA1C % † 5.7 ± 0.8 5.8 ± 0.7 0.88
* Median (25-75% percentiles); † Mean ± SD
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Table 3: Characteristics of patients with (V)LST.
Characteristic
Discontinuation of 
clopidogrel, n (%)
20 (100)
Clopidogrel free interval 
prior to (V)LST (days, median, 
range)
202 (1433)
Discontinuation of 
acetylsalicylic acid n (%)
2 (10)
Acetylsalicylic acid free 
interval prior to (V)LST (days, 
median, range)
0 (180)
Late Stent thrombosis (6-12 
months) n (%)
6 (30)
Very late stent thrombosis (> 
12 months) n (%)
14 (70)
Vessel with stent thrombosis
LAD n (%) 12 (60)
CX n (%) 3 (15)
RCA n (%) 5 (25)
Multivessel stenting prior to 
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